Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Outlook
  • Published:

PSMA-PET to detect prostate cancer recurrence after radiotherapy

Nature Reviews Urology volume 20, pages 5–6 (2023)Cite this article

Subjects

PSA dynamics and conventional imaging methods currently used to assess biochemical recurrence of prostate cancer after definitive treatment with radiotherapy are insufficient, especially considering that different salvage options are available. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) is a novel imaging method that was shown to be more accurate than conventional imaging in prostate cancer staging, and can have a role in detecting disease recurrence after radiotherapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Liu, W. et al. A prospective study of 18F-DCFPyL PSMA PET/CT restaging in recurrent prostate cancer following primary external beam radiotherapy or brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 106, 546–555 (2020).

    Article  Google Scholar 

  2. Roach, M. III et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int. J. Radiat. Oncol. Biol. Phys. 65, 965–974 (2006).

    Article  Google Scholar 

  3. Alghazo, O. et al. The application of theranostics in different stages of prostate cancer. Future Oncol. 17, 3637–3644 (2021).

    Article  Google Scholar 

  4. Hofman, M. S. et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395, 1208–1216 (2020).

    Article  Google Scholar 

  5. Hövels, A. M. et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin. Radiol. 63, 387–395 (2008).

    Article  Google Scholar 

  6. Shen, G., Deng, H., Hu, S. & Jia, Z. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol. 43, 1503–1513 (2014).

    Article  Google Scholar 

  7. Einspieler, I. et al. Detection efficacy of hybrid 68Ga-PSMA ligand PET/CT in prostate cancer patients with biochemical recurrence after primary radiation therapy defined by Phoenix Criteria. J. Nucl. Med. 58, 1081–1087 (2017).

    Article  Google Scholar 

  8. Raveenthiran, S. et al. The use of 68Ga-PET/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy. Prostate Cancer Prostatic Dis. 22, 385–390 (2019).

    Article  Google Scholar 

  9. Jansen, B. H. E. et al. Detection of recurrent prostate cancer using prostate-specific membrane antigen positron emission tomography in patients not meeting the Phoenix Criteria for biochemical recurrence after curative radiotherapy. Eur. Urol. Oncol. 4, 821–825 (2021).

    Article  Google Scholar 

  10. Pfister, D. et al. 68Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer. BJU Int. 126, 679–683 (2020).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia

    Omar Alghazo & Michael O’Callaghan

  2. Royal Darwin Hospital, Tiwi, Northern Territory, Australia

    Omar Alghazo

  3. Urology Unit, Flinders Medical Centre, Bedford Park, South Australia, Australia

    Michael O’Callaghan

  4. Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia

    Michael O’Callaghan

Authors
  1. Omar Alghazo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael O’Callaghan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Omar Alghazo.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alghazo, O., O’Callaghan, M. PSMA-PET to detect prostate cancer recurrence after radiotherapy. Nat Rev Urol 20, 5–6 (2023). https://doi.org/10.1038/s41585-022-00672-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-022-00672-4

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer